UChicago Medicine to Offer CAR T-Cell Therapy for Cancer – The Chicago Maroon
|
UChicago Medicine to Offer CAR T-Cell Therapy for Cancer
The Chicago Maroon University of Chicago Medicine became the first site in Illinois to offer a new treatment, CAR T-cell therapy, for patients with relapsed or refractory diffuse large-B cell lymhophoma (DLBCL), a type of non-Hodgkin’s lymphoma. The new immunotherapeutic … |
Medical Xpress |
Scientists discover surprising immune cell activity that may be limiting immunotherapy
Medical Xpress Cancer immunotherapy treatments work by supercharging the immune system to fight cancer. So when Tregs come in and suppress the immune response, it shuts down the cancer-fighting effect. But eliminating the Tregs doesn’t help. Researchers have tried … |
Endpoints News |
Sanofi Genzyme retreats from its Parkinson’s deal with gene therapy upstart Voyager, part of an $845M pact
Endpoints News Sanofi $SNY gambled $100 million upfront in early 2015 on the hot gene therapy field, promising Voyager up to $745 million in milestones for their partnership on a full slate of development programs, capped by the leading Parkinson’s effort. Voyager … Voyager Therapeutics Announces Update to Parkinson’s Disease ProgramMarkets Insider |